These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17667928)

  • 21. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.
    Kim EJ; Ben-Josef E; Herman JM; Bekaii-Saab T; Dawson LA; Griffith KA; Francis IR; Greenson JK; Simeone DM; Lawrence TS; Laheru D; Wolfgang CL; Williams T; Bloomston M; Moore MJ; Wei A; Zalupski MM
    Cancer; 2013 Aug; 119(15):2692-700. PubMed ID: 23720019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer.
    Muler JH; McGinn CJ; Normolle D; Lawrence T; Brown D; Hejna G; Zalupski MM
    J Clin Oncol; 2004 Jan; 22(2):238-43. PubMed ID: 14665608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
    Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
    Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial.
    Reni M; Balzano G; Zanon S; Zerbi A; Rimassa L; Castoldi R; Pinelli D; Mosconi S; Doglioni C; Chiaravalli M; Pircher C; Arcidiacono PG; Torri V; Maggiora P; Ceraulo D; Falconi M; Gianni L
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):413-423. PubMed ID: 29625841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic mycoplasma-derived lipopeptide MALP-2 induces maturation and function of dendritic cells.
    Weigt H; Mühlradt PF; Emmendörffer A; Krug N; Braun A
    Immunobiology; 2003; 207(3):223-33. PubMed ID: 12777064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
    Motoi F; Satoi S; Honda G; Wada K; Shinchi H; Matsumoto I; Sho M; Tsuchida A; Unno M;
    J Gastroenterol; 2019 Feb; 54(2):194-203. PubMed ID: 30182219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TLR2/6 stimulation of the rat lung: effects on lymphocyte subsets, natural killer cells and dendritic cells in different parts of the air-conducting compartments and at different ages.
    Pabst R; Durak D; Roos A; Lührmann A; Tschernig T
    Immunology; 2009 Jan; 126(1):132-9. PubMed ID: 18565128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
    Landry J; Catalano PJ; Staley C; Harris W; Hoffman J; Talamonti M; Xu N; Cooper H; Benson AB
    J Surg Oncol; 2010 Jun; 101(7):587-92. PubMed ID: 20461765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
    Oettle H; Post S; Neuhaus P; Gellert K; Langrehr J; Ridwelski K; Schramm H; Fahlke J; Zuelke C; Burkart C; Gutberlet K; Kettner E; Schmalenberg H; Weigang-Koehler K; Bechstein WO; Niedergethmann M; Schmidt-Wolf I; Roll L; Doerken B; Riess H
    JAMA; 2007 Jan; 297(3):267-77. PubMed ID: 17227978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88-dependent signaling pathway.
    Takeuchi O; Kaufmann A; Grote K; Kawai T; Hoshino K; Morr M; Mühlradt PF; Akira S
    J Immunol; 2000 Jan; 164(2):554-7. PubMed ID: 10623793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
    Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L
    Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
    Scheithauer W; Kornek GV; Raderer M; Hejna M; Valencak J; Miholic J; Kovats E; Lang F; Funovics J; Bareck E; Depisch D
    Br J Cancer; 1999 Aug; 80(11):1797-802. PubMed ID: 10468299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
    Sherman WH; Chu K; Chabot J; Allendorf J; Schrope BA; Hecht E; Jin B; Leung D; Remotti H; Addeo G; Postolov I; Tsai W; Fine RL
    Cancer; 2015 Mar; 121(5):673-80. PubMed ID: 25492104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intracutaneous injection of the macrophage-activating lipopeptide-2 (MALP-2) which accelerates wound healing in mice--a phase I trial in 12 patients.
    Niebuhr M; Mühlradt PF; Wittmann M; Kapp A; Werfel T
    Exp Dermatol; 2008 Dec; 17(12):1052-6. PubMed ID: 18713273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer.
    Löhr JM; Karimi M; Omazic B; Kartalis N; Verbeke CS; Berkenstam A; Frödin JE
    Pancreatology; 2016; 16(4):640-5. PubMed ID: 27234064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma.
    Wilkowski R; Thoma M; Dühmke E; Rau HG; Heinemann V
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):768-72. PubMed ID: 14967432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft.
    Pratesi G; Petrangolini G; Tortoreto M; Addis A; Belluco S; Rossini A; Selleri S; Rumio C; Menard S; Balsari A
    Cancer Res; 2005 Jul; 65(14):6388-93. PubMed ID: 16024642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results.
    Sinn M; Liersch T; Riess H; Gellert K; Stübs P; Waldschmidt D; Lammert F; Maschmeyer G; Bechstein W; Bitzer M; Denzlinger C; Hofheinz R; Lindig U; Ghadimi M; Hinke A; Striefler JK; Pelzer U; Bischoff S; Bahra M; Oettle H
    Eur J Cancer; 2020 Oct; 138():172-181. PubMed ID: 32890813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas.
    Feliu J; Mel R; Borrega P; López Gómez L; Escudero P; Dorta J; Castro J; Vázquez-Estévez SE; Bolaños M; Espinosa E; González Barón M;
    Ann Oncol; 2002 Nov; 13(11):1756-62. PubMed ID: 12419748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.
    Philip PA; Zalupski MM; Vaitkevicius VK; Arlauskas P; Chaplen R; Heilbrun LK; Adsay V; Weaver D; Shields AF
    Cancer; 2001 Aug; 92(3):569-77. PubMed ID: 11505401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.